Back
Alnylam Pharmaceuticals Quote, Financials, Valuation and Earnings
Sell
28
ALNY
Alnylam Pharmaceuticals
Last Price:
151.38
Seasonality Move:
19.79%
7 Day Trial
ALL ACCESS PASS
$
7
Alnylam Pharmaceuticals Price Quote
$151.38
+3.98 (+2.7%)
(Updated: May 16, 2024 at 6:55 PM ET)
Alnylam Pharmaceuticals Key Stats
Sell
28
Alnylam Pharmaceuticals (ALNY)
is a Sell
Day range:
$146.97 - $151.15
52-week range:
$141.98 - $218.88
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
9.34
P/B ratio:
0%
Volume:
536.1K
Avg. volume:
490.6K
1-year change:
-28.52%
Market cap:
$18.6B
Revenue:
$1.8B
EPS:
$-2.68
How Much Does Alnylam Pharmaceuticals Make?
-
How Much Are Alnylam Pharmaceuticals's Sales Annually?
ALNY Revenues are $1.8B -
How Much Profit Does Alnylam Pharmaceuticals's Make A Year?
ALNY net income is -$440.2M
Is Alnylam Pharmaceuticals Growing As A Company?
-
What Is Alnylam Pharmaceuticals's Growth Rate Quarterly?
Quarterly YoY revenue growth is 0.55% -
What Is Alnylam Pharmaceuticals's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Alnylam Pharmaceuticals Stock Price Performance
-
Did Alnylam Pharmaceuticals Stock Go Up Last Month?
Alnylam Pharmaceuticals share price went down by -0.2% last month -
Did ALNY's Share Price Rise Over The Last Year?
ALNY share price fell by -28.52% over the past 1 year
What Is Alnylam Pharmaceuticals 52-Week High & Low?
-
What Is Alnylam Pharmaceuticals’s 52-Week High Share Price?
Alnylam Pharmaceuticals has traded as high as $218.88 over the past 52 weeks -
What Is Alnylam Pharmaceuticals’s 52-Week Low Share Price?
Alnylam Pharmaceuticals has traded as low as $141.98 over the past 52 weeks
Alnylam Pharmaceuticals Price To Free Cash Flow
-
Is Alnylam Pharmaceuticals Stock Overvalued?
Alnylam Pharmaceuticals is trading at a price to free cash flow ratio of 146.38 -
Is Alnylam Pharmaceuticals Stock Undervalued?
Alnylam Pharmaceuticals EV to Free Cash Flow ratio is 135.31 -
What Is Alnylam Pharmaceuticals’s Price Earnings Growth Ratio?
ALNY PEG ratio is 0.00 -
Is Alnylam Pharmaceuticals Trading At A Premium To Earnings?
Alnylam Pharmaceuticals EV to EBIT ratio is 0.00
Is It Risky To Buy Alnylam Pharmaceuticals?
-
How Much Debt Does Alnylam Pharmaceuticals Have?
Total long term debt quarterly is $1B -
How Much Cash Does Alnylam Pharmaceuticals Have?
Cash and short term investments quarterly total is $2.4B -
What Is Alnylam Pharmaceuticals’s Book Value Per Share?
Book value per share is -1.73
Is Alnylam Pharmaceuticals Cash Flow Positive?
-
What Is ALNY Cash Flow From Operations?
Cash flow from operations (TTM) is $189.1M -
What Is Alnylam Pharmaceuticals’s Cash Flow From Financing?
Cash flow from financing (TTM) is $154.7M -
What Is Alnylam Pharmaceuticals’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$327.8M
Alnylam Pharmaceuticals Return On Invested Capital
-
Is Management Doing A Good Job?
ALNY return on invested capital is -43.4% -
What Is Alnylam Pharmaceuticals Return On Assets?
ROA measures how assets are converting to revenues and is -9.08% -
What Is ALNY Return On Equity?
ROE is a measure of profitability and is 0%
Alnylam Pharmaceuticals Earnings Date & Stock Price
-
What Is Alnylam Pharmaceuticals's Stock Price Today?
A single share of ALNY can be purchased today for 147.40 -
What Is Alnylam Pharmaceuticals’s Stock Symbol?
Alnylam Pharmaceuticals trades on the nasdaq under the ticker symbol: ALNY -
When Is Alnylam Pharmaceuticals’s Next Earnings Date?
The next quarterly earnings date for Alnylam Pharmaceuticals is scheduled on August 2, 2024 -
When Is ALNY's next ex-dividend date?
Alnylam Pharmaceuticals's next ex-dividend date is May 17, 2024 -
How To Buy Alnylam Pharmaceuticals Stock?
You can buy Alnylam Pharmaceuticals shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Alnylam Pharmaceuticals Competitors
-
Who Are Alnylam Pharmaceuticals's Competitors?
Below is a list of companies who compete with Alnylam Pharmaceuticals or are related in some way:
Alnylam Pharmaceuticals Dividend Yield
Data Unavailable
Alnylam Pharmaceuticals Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 0% | 74.5% |
| Revenue: | 54.82% | 15.82% |
Analyst Recommendations
| Buy Recommendations: | 11 |
|---|---|
| Hold Recommendations: | 9 |
| Sell Recommendations: | 0 |
| Price Target: | 220.38 |
| Upside from Last Price: | 49.51% |